Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 39

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018

Summary

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 7 and 4 respectively.

Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Hematological Tumor, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chondrosarcoma, Glioblastoma Multiforme (GBM), Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer and Pancreatic Cancer.

The latest report Myc Proto Oncogene Protein - Pip Review, H2 2018, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

- The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects

- The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pip Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Companies Involved in Therapeutics Development
Peptomyc SL
Phylogica Ltd
Sorrento Therapeutics Inc
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Drug Profiles
BGA-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ES-4000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galarmin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit c-Myc for Solid Tumors and Hematological Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMO-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit cMyc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MYC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Peptomyc SL, H2 2018
Pipeline by Phylogica Ltd, H2 2018
Pipeline by Sorrento Therapeutics Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Herceptin Biosimilar Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 123
    Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein. Scope of the Report: The worldwide market for Herceptin Biosimilar is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, fr......
  • Global Cancer Immunotherapy Drug Discovery Outsourcing Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 116
    Scope of the Report: The global Cancer Immunotherapy Drug Discovery Outsourcing market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. ......
  • Global Antibiotic Resistance Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 116
    Antibiotic are medicines that are used to prevent various bacterial infections and antibiotic resistance is the inability of a microorganism to withstand the effects of an antibiotic. It is a specific type of drug resistance. These bacteria may infect humans and animals body, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Hence, antibiotic resistance leads to higher medical costs and increased mortality. Scope of the Report: T......
  • Global Neuroendocrine Tumors (NETs) Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 119
    Neuro Emotional Technique (NET) is a psycho-emotional therapy based on the physiological foundations of stress-related responses. As discovered in the late 1970's, emotional responses are composed of neuropeptides (amino acid chains) and their receptors, which lie on neurons and other cells of remote tissues in the body. The neuropeptides are ejected from the neuron and carry the encoded "information" to other sites within the body. These neuropeptides are in a category of neurochemicals known a......
  • Global Cervical Cancer Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 121
    Scope of the Report: The worldwide market for Cervical Cancer Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Cervical Cancer Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, reg......
  • Global Nasal Drug Delivery Technology Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 139
    Scope of the Report: The worldwide market for Nasal Drug Delivery Technology is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Nasal Drug Delivery Technology in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufact......
  • Global Pharmacovigilance (PV) Outsourcing Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 135
    Scope of the Report: The global Pharmacovigilance (PV) Outsourcing market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes f......
  • Global Biopharmaceutical Excipients Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 120
    Scope of the Report: The worldwide market for Biopharmaceutical Excipients is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Biopharmaceutical Excipients in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturer......
  • Global API Contract Manufacturing Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 18-Jun-2019        Price: US 3480 Onwards        Pages: 117
    Contract manufacturing is the process where manufacturer engages into an agreement with the companies for component or product manufacturing. Active pharmaceutical ingredient (API) contract manufacturing refers to the development of pharmaceutical drugs through contract manufacturing by outsourcing to other companies. Scope of the Report: The global API Contract Manufacturing market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 20......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs